International Breast Cancer Study Group trials.

[1]  F. Cavalli,et al.  Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. , 1998, European journal of cancer.

[2]  C. Hürny,et al.  Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials. , 1998, British Journal of Cancer.

[3]  R. Gelber,et al.  Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach , 1998 .

[4]  M. Tattersall,et al.  Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. , 1997, European journal of cancer.

[5]  F. Cavalli,et al.  Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  R. Gelber,et al.  Prognostic importance of thymidylate synthase expression in early breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Zelen,et al.  Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Forbes,et al.  Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer , 1996, The Lancet.

[9]  A M Stiggelbout,et al.  The ‘Utility’ of the Visual Analog Scale in Medical Decision Making and Technology Assessment: Is It an Alternative to the Time Trade-off? , 1996, International Journal of Technology Assessment in Health Care.

[10]  S. Green,et al.  Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[12]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[13]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[14]  C. J. Williams,et al.  Introducing new treatments for cancer : practical, ethical and legal problems , 1992 .

[15]  R. Nissen-Meyer,et al.  Perioperative adjuvant chemotherapy in breast cancer. The Scandinavian Adjuvant Chemotherapy Study 1. , 1989, Acta oncologica.

[16]  M. Zelen,et al.  Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. , 1989, The New England journal of medicine.

[17]  P Glasziou,et al.  Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  G. Bonadonna,et al.  Salvage treatments in relapsing resectable breast cancer. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[19]  R. Gelber,et al.  A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Zelen,et al.  A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. , 1985, Cancer research.

[21]  Ludwig Breast.  Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Redmond,et al.  Treatment of primary breast cancer with chemotherapy and tamoxifen. , 1981, The New England journal of medicine.

[23]  N. M. Drayer,et al.  STERILITY PROBLEMS AND THE DIABETIC , 1978, The Lancet.

[24]  G. Bonadonna,et al.  Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.

[25]  C. Redmond,et al.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. , 1975, The New England journal of medicine.